Organic nitrates: Update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction

Vascular Pharmacology

Volumn 63, Issue 3, 2014, Pages 105-113

  Münzel, Thomas ^a   Steven, Sebastian ^a   Daiber, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Endothelin; Isosorbide mono and dinitrate; Nitroglycerin; Pentaerythrityl tetranitrate; Tolerance

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALDOSTERONE; BILIRUBIN; CARBON MONOXIDE; CATECHOLAMINE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ENDOTHELIN; ENDOTHELIN 1; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEME OXYGENASE 1; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MANGANESE SUPEROXIDE DISMUTASE; MYOSIN LIGHT CHAIN PHOSPHATASE; PENTAERYTHRITYL TETRANITRATE; PEROXYNITRITE; PHOSPHOLIPASE C; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASOCONSTRICTOR AGENT; VASOPRESSIN; NITRIC ACID DERIVATIVE; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; BIOAVAILABILITY; CATECHOLAMINE RELEASE; CELLULAR DISTRIBUTION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CROSS TOLERANCE; CYTOPLASM; DESENSITIZATION; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXERCISE; HUMAN; HYPERTENSION; MITOCHONDRION; NITROSYLATION; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; REVIEW; S NITROSYLATION; SMOOTH MUSCLE FIBER; SPIN TRAPPING; SUPERSENSITIVITY; TREADMILL EXERCISE; UPREGULATION; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION; VASOPRESSIN BLOOD LEVEL; ANIMAL; DRUG EFFECTS; DRUG TOLERANCE; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

ANIMALS; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; VASCULAR DISEASES; VASODILATION; VASODILATOR AGENTS;

EID: 84918833924     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.09.002     Document Type: Review

References (79)

1. Task Force Members, Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34:2949-3003.
2. Parker J.D., Farrell B., Fenton T., Cohanim M., Parker J.O. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991, 84:2336-2345.
3. Rapoport R.M., Waldman S.A., Ginsburg R., Molina C.R., Murad F. Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 1987, 10:82-89.
4. Kim D., Rybalkin S.D., Pi X., Wang Y., Zhang C., Munzel T., et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001, 104:2338-2343.
5. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995, 95:187-194.
6. Munzel T., Giaid A., Kurz S., Stewart D.J., Harrison D.G. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci 1995, 92:5244-5248.
7. Oelze M., Knorr M., Kroller-Schon S., Kossmann S., Gottschlich A., Rummler R. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J 2013, 34:3206-3216.
8. Hink U., Oelze M., Kolb P., Bachschmid M., Zou M.H., Daiber A., et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 2003, 42:1826-1834.
9. Munzel T., Sinning C., Post F., Warnholtz A., Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008, 40:180-196.
10. Schlossmann J., Feil R., Hofmann F. Insights into cGMP signalling derived from cGMP kinase knockout mice. Front Biosci 2005, 10:1279-1289.
11. Colussi C., Scopece A., Vitale S., Spallotta F., Mattiussi S., Rosati J., et al. P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N(epsilon)-lysine acetylation of contractile proteins. Arterioscler Thromb Vasc Biol 2012, 32:2435-2443.
12. Kleschyov A.L., Oelze M., Daiber A., Huang Y., Mollnau H., Schulz E., et al. Does nitric oxide mediate the vasodilator activity of nitroglycerin?. Circ Res 2003, 93:e104-e112.
13. Nunez C., Victor V.M., Tur R., Alvarez-Barrientos A., Moncada S., Esplugues J.V., et al. Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circ Res 2005, 97:1063-1069.
14. Pautz A., Rauschkolb P., Schmidt N., Art J., Oelze M., Wenzel P., et al. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics 2009, 38:176-185.
15. Chen Z., Zhang J., Stamler J.S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002, 99:8306-8311.
16. Sydow K., Daiber A., Oelze M., Chen Z., August M., Wendt M., et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004, 113:482-489.
17. Zhang J., Chen Z., Cobb F.R., Stamler J.S. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation 2004, 110:750-755.
18. Daiber A., Oelze M., Coldewey M., Bachschmid M., Wenzel P., Sydow K., et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 2004, 66:1372-1382.
19. Chen Z., Foster M.W., Zhang J., Mao L., Rockman H.A., Kawamoto T., et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2005, 102:12159-12164.
20. Beretta M., Gruber K., Kollau A., Russwurm M., Koesling D., Goessler W., et al. Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases. J Biol Chem 2008, 283:17873-17880.
21. Tsou P.S., Page N.A., Lee S.G., Fung S.M., Keung W.M., Fung H.L. Differential metabolism of organic nitrates by aldehyde dehydrogenase 1a1 and 2: substrate selectivity, enzyme inactivation, and active cysteine sites. AAPS J 2011, 13:548-555.
22. Lin S., Page N.A., Fung S.M., Fung H.L. In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1. Nitric Oxide 2013, 35:137-143.
23. Elkayam U., Kulick D., McIntosh N., Roth A., Hsueh W., Rahimtoola S.H. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987, 76:577-584.
24. Munzel T., Heitzer T., Kurz S., Harrison D.G., Luhman C., Pape L., et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol 1996, 27:297-303.
25. Parker J.D., Parker A.B., Farrell B., Parker J.O. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995, 91:973-978.
26. Gori T., Floras J.S., Parker J.D. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol 2002, 40:2000-2005.
27. Mulsch A., Busse R., Bassenge E. Desensitization of guanylate cyclase in nitrate tolerance does not impair endothelium-dependent responses. Eur J Pharmacol 1988, 158:191-198.
28. Molina C.R., Andresen J.W., Rapoport R.M., Waldman S., Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 1987, 10:371-378.
29. Sayed N., Baskaran P., Ma X., van den Akker F., Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A 2007, 104:12312-12317.
30. Zhou Z., Sayed N., Pyriochou A., Roussos C., Fulton D., Beuve A., et al. Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Arterioscler Thromb Vasc Biol 2008, 28:1803-1810.
31. Gori T., Harvey P., Floras J.S., Parker J.D. Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol 2004, 44:601-606.
32. Gori T., Mak S.S., Kelly S., Parker J.D. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 2001, 38:1096-1101.
33. Caramori P.R., Adelman A.G., Azevedo E.R., Newton G.E., Parker A.B., Parker J.D. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998, 32:1969-1974.
34. Azevedo E.R., Schofield A.M., Kelly S., Parker J.D. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001, 37:505-509.
35. Schulz E., Tsilimingas N., Rinze R., Reiter B., Wendt M., Oelze M., et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002, 105:1170-1175.
36. Warnholtz A., Mollnau H., Heitzer T., Kontush A., Moller-Bertram T., Lavall D., et al. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 2002, 40:1356-1363.
37. Sage P.R., de la Lande I.S., Stafford I., Bennett C.L., Phillipov G., Stubberfield J., et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000, 102:2810-2815.
38. Jurt U., Gori T., Ravandi A., Babaei S., Zeman P., Parker J.D. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 2001, 38:854-859.
39. McVeigh G.E., Hamilton P., Wilson M., Hanratty C.G., Leahey W.J., Devine A.B., et al. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation 2002, 106:208-213.
40. Wenzel P., Hink U., Oelze M., Schuppan S., Schaeuble K., Schildknecht S., et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 2007, 282:792-799.
41. Esplugues J.V., Rocha M., Nunez C., Bosca I., Ibiza S., Herance J.R., et al. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res 2006, 99:1067-1075.
42. Daiber A., Oelze M., Sulyok S., Coldewey M., Schulz E., Treiber N., et al. Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol 2005, 68:579-588.
43. Needleman P., Hunter F.E. Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action. Mol Pharmacol 1966, 2:134-143.
44. Oelze M., Knorr M., Schell R., Kamuf J., Pautz A., Art J., et al. Regulation of human mitochondrial aldehyde dehydrogenase (ALDH-2) activity by electrophiles in vitro. J Biol Chem 2011, 286:8893-8900.
45. Wenzel P., Mollnau H., Oelze M., Schulz E., Wickramanayake J.M., Muller J., et al. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal 2008, 10:1435-1447.
46. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al-Hesayen A., Kelly S., et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001, 104:1119-1123.
47. Munzel T., Li H., Mollnau H., Hink U., Matheis E., Hartmann M., et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000, 86:E7-E12.
48. Knorr M, Hausding M, Kroller-Schuhmacher S, Steven S, Oelze M, Heeren T, Scholz A, Gori T, Wenzel P, Schulz E, Daiber A and Munzel T. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol. 31:2223-31.
49. Gruhn N., Aldershvile J., Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol 2001, 416:245-249.
50. Kahler J., Ewert A., Weckmuller J., Stobbe S., Mittmann C., Koster R., et al. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 2001, 38:49-57.
51. Kahler J., Mendel S., Weckmuller J., Orzechowski H.D., Mittmann C., Koster R., et al. Oxidative stress increases synthesis of Big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 2000, 32:1429-1437.
52. Heitzer T., Just H., Brockhoff C., Meinertz T., Olschewski M., Munzel T. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998, 31:83-88.
53. Thomas G.R., DiFabio J.M., Gori T., Parker J.D. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007, 49:1289-1295.
54. Nakamura Y., Moss A.J., Brown M.W., Kinoshita M., Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999, 138:577-585.
55. Gori T., Al-Hesayen A., Jolliffe C., Parker J.D. Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol 2003, 91:1392-1394.
56. Hacker A., Muller S., Meyer W., Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol 2001, 132:1707-1714.
57. Oberle S., Abate A., Grosser N., Hemmerle A., Vreman H.J., Dennery P.A., et al. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood) 2003, 228:529-534.
58. Wenzel P., Oelze M., Coldewey M., Hortmann M., Seeling A., Hink U., et al. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 2007, 27:1729-1735.
59. Schuhmacher S., Wenzel P., Schulz E., Oelze M., Mang C., Kamuf J., et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010, 55:897-904.
60. Oppermann M., Balz V., Adams V., Dao V.T., Bas M., Suvorava T., et al. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med 2009, 13:1271-1278.
61. Munzel T., Meinertz T., Tebbe U., Schneider H.T., Stalleicken D., Wargenau M., et al. Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial. Eur Heart J 2014, 35:895-903.
62. Parker J.O., Fung H.L., Ruggirello D., Stone J.A. Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation 1983, 68:1074-1080.
63. Thadani U., Fung H.L., Darke A.C., Parker J.O. Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy. Circulation 1980, 62:491-502.
64. Thadani U., Manyari D., Parker J.O., Fung H.L. Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 1980, 61:526-535.
65. Thadani U., Fung H.L., Darke A.C., Parker J.O. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol 1982, 49:411-419.
66. Sekiya M., Sato M., Funada J., Ohtani T., Akutsu H., Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005, 46:63-67.
67. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
68. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
69. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino R., Ferdinand K., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
70. Daiber A., Oelze M., Coldewey M., Kaiser K., Huth C., Schildknecht S., et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 2005, 338:1865-1874.
71. Munzel T., Kurz S., Rajagopalan S., Thoenes M., Berrington W.R., Thompson J.A., et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996, 98:1465-1470.
72. Hare J.M. Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004, 351:2112-2114.
73. Thum T., Fraccarollo D., Thum S., Schultheiss M., Daiber A., Wenzel P., et al. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 2007, 27:748-754.
74. Keimer R., Stutzer F.K., Tsikas D., Troost R., Gutzki F.M., Frolich J.C. Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythrityl tetranitrate in healthy humans: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 2003, 41:284-292.
75. Munzel T., Daiber A., Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J 2013, 34:2666-2673.
76. Martens D., Kojda G. Impaired vasodilator response to organic nitrates in isolated basilar arteries. Br J Pharmacol 2001, 132:30-36.
77. Minamiyama Y., Takemura S., Imaoka S., Funae Y., Okada S. Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates. Drug Metab Pharmacokinet 2007, 22:15-19.
78. Schnorbus B., Schiewe R., Ostad M.A., Medler C., Wachtlin D., Wenzel P., et al. Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study. Clin Res Cardiol 2011, 99:115-124.
79. Munzel T., Holtz J., Mulsch A., Stewart D.J., Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989, 79:188-197.